BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...
Manuka honey comes from the manuka plant, officially known as Leptospermum scoparium. The plant is a bush native to New ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
In a report released on December 19, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a c ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...
Mehdi obtained his MSc Degree in “Molecular Interactions and Therapeutics” from Jules Verne University of Amiens (France). In ...
Use of antibiotics by the newborn or mother while breastfeeding, dietary changes, bacterial infections, parasite infections, and cystic fibrosis are among the major causes of diarrhea in infants. Thus ...